DOSAGE INDEX / SINGLE
Selank
Research, reported schedules and supply planning.
Evaluate Selank patient comparisons, acute brain-imaging findings and animal evidence, with clear limits on equivalence, cognitive and safety claims.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 300 micrograms per administration in its product-reference example; separately reported studies differ
- Frequency
- Three times daily in that example
- Cycle / observation period
- 14 days in that example
- Route / research model
- Intranasal
The source distinguishes manufactured nasal drops from custom solutions. Pump output, preservation and formulation are not interchangeable.
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Intranasal formulation: preservative, tonicity and delivery-device compatibility must be verified. Injectable bacteriostatic water is not assigned as the default nasal vehicle.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 5 mg | Enter a total |
| 10 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- A 2008 report compared Selank in 30 patients with medazepam in 32 patients who had generalized anxiety disorder or neurasthenia. The investigators used Hamilton, Zung and CGI scales and also measured an enkephalin-related serum parameter. They reported similar anxiety-reducing effects, with additional antiasthenic and psychostimulant effects attributed to Selank. [1]
- A 2020 study assessed 52 healthy participants using resting-state fMRI before and shortly after Selank, Semax or placebo. It reported differences in functional connectivity involving the right amygdala and temporal cortical regions. This was an acute imaging experiment, not evidence of lasting anxiety remission or improved work performance. [2]
- In a rat model involving 6-OHDA injury, Selank reduced an anxiety-related measure, while neither Selank nor Semax improved the reported motor-activity or passive-defensive-behavior outcomes. The paper therefore does not establish reversal of the modeled motor impairment. [4]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 14 entries mapped from 2 source pages. Medical and supporting references are retained below; supplier entries are excluded.
- Original anxiety comparison
- original imaging study
- Medvedev and colleagues, original report
- Original rat study
- FDA safety resource
- Syunyakov et al. (2012)Further reading · Listed in reference bibliography.
- Panikratova et al. (2020)Further reading · Listed in reference bibliography.
- Trows et al. (2014)Further reading · Listed in reference bibliography.
- U.S. Food and Drug AdministrationRegulatory / product information · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.